Security Reports > Editas Medicine

Editas Medicine
Data Breaches, Cyber Attacks and Security Report

https://editasmedicine.com  ᛫ 
Last updated August 14, 2020

Editas Medicine Security Rating

${grade.letter}
${cstarScore}
/ 950

UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Editas Medicine is implementing good security practices.

Company Information

Company:
${companyName}
Valuation:
${marketCap}
Employees:
${employees}
Location:
${country}
CEO:
${ceo}

About Editas Medicine

Editas Medicine is a discovery-phase pharmaceutical company based in Cambridge, Massachusetts which aims to develop therapies based on CRISPR–Cas9 gene editing technology. It was founded in 2013 with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures and licensed CRISPR patents from the Broad Institute's Feng Zhang, patents from Harvard's David Liu and George Church and patents from Partners Healthcare-MGH's J. Keith Joung.


Data Breaches and Security News


Security Report for Editas Medicine

Want a security rating for your organization?

This report shows a preliminary security rating for Editas Medicine. UpGuard scans billions of digital assets daily, in depth, across thousands of vectors. Data leak detection, vulnerability scanning and identity breach detection are just some of the advanced capabilities offered by the UpGuard platform.

Get a deeper scan

Related posts

Read more about the latest issues in cybersecurity

More security reports

Compare Editas Medicine's security performance with other companies